Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The Oxford-Mount Sinai (OxMS) Preprint Journal Club has partnered with Nature Reviews Immunology to launch a monthly Preprint Watch column.

Pile of papers on a table

Launching in the February issue of Nature Reviews Immunology, the Preprint Watch column is designed to provide rapid and open access to early data on both COVID-19 and non-COVID-19 immunology preprints. The first two reviews are: Super(antigen) target for SARS-CoV-2 and Sensing our Z-RNA.

During the COVID-19 pandemic the pace of scientific discovery and the race to find solutions required swift communication of results and fuelled an increase in immunology preprints. Journal club communities around the world seized the opportunity to evaluate and critically analyse a large number of SARS-CoV-2 preprints to provide independent insights to frontline researchers, to the general public, and to help prevent misinformation.

The journal group at Precision Immunology Institute at the Icahn School of Medicine, New York, and the OxImmuno Literature Initiative at the University of Oxford were both producing regular preprint summaries related to the COVID-19 emergency. Towards the end of 2020, the journal club teams from both institutes joined forces to launch the Oxford-Mount Sinai (OxMS) preprint journal club. During a weekly virtual joint ‘journal club’ they discuss selected preprints using their cross-institutional expertise and find the latest advancement in immunology. This new way of assessing and reviewing preprint literature may become a new approach to academic peer reviewing.

Felix Richter, Wellcome Trust DPhil student and co-founder of the OxMS Journal Club initiative at NDORMS said: “We are very happy to have started the first cross-institutional preprint journal club in collaboration with Nature Reviews Immunology and our colleagues at Mount Sinai School of Medicine. The aim of this community-based initiative is to identify trends in up-and-coming literature in immunology. It further provides a training opportunity for early career researchers to assess primary research data and provide constructive feedback to peers in the field.  We hope it will be of benefit to the preprint authors by providing useful suggestions to improve their research and by highlighting their research strengths.

We believe that other journal clubs around the world can use our approach to create more of these ‘preprint club hubs’ for immunology or other fields of science. The partnership with other international Institutes, publishers and organisations specialised on providing peer-review training to early career researchers is key to the success of this initiative.”

The launch edition of the Preprint Watch column comes with an editorial from Nature Reviews Immunology that explains the rationale for covering preprints and the precautions that must be considered with their use. 

Similar stories

Fat tissues can play a protective role against inflammation in the intestine

A new study in The EMBO Journal has revealed how fat tissues might provide a protective role in intestinal inflammation opening new lines of research into the treatment of inflammatory bowel diseases.

Communication at the crossroads of the immune system

In his inaugural article in the Proceedings of the National Academy of Sciences as an NAS member (elected 2021), Prof Mike Dustin and his research team have explained how messages are passed across the immunological synapse. The research could have implications for future vaccine development and immunotherapy treatments.

New drug offers hope for people with hand osteoarthritis

A new study, published in Science Translational Medicine by researchers at the University of Oxford has identified that Talarozole, a drug that is known to increase retinoic acid, was able to prevent osteoarthritis (OA) in disease models.

Adalimumab is found to be a cost-effective treatment for early-stage Dupuytren’s disease

Researchers at the Kennedy Institute of Rheumatology and Oxford Population Health’s Health Economics Research Centre have found that anti-TNF treatment (adalimumab) is likely to be a cost-effective treatment for people affected by early-stage Dupuytren’s disease.

MRC funding awarded to Kennedy researchers

Two new projects led by Tal Arnon and Irina Udalova have been awarded Medical Research Council (MRC) funding.

Breakthrough in treatment for Dupuytren’s disease

Injection of the anti-TNF drug adalimumab into Dupuytren’s disease nodules is effective in reducing nodule hardness and nodule size.